Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
Text
Arcalyst® (rilonacept) – New orphan indication
March 18, 2021 - Kiniksa Pharmaceuticals announced the FDA approval of Arcalyst (rilonacept), for the treatment of recurrent pericarditis and reduction in risk of recurrence in adults and pediatric patients 12 years and older.
